Highlights Newsletter 2

This newsletter presents you the following key sessions:

1. Podcast with Prof. Richard S. Finn about lenvatinib plus pembrolizumab vs. lenvatinib as first-line therapy
    for advanced hepatocellular carcinoma

2. Optimal duration of androgen deprivation therapy in combination with post-operative radiotherapy for
    prostate cancer

3. A new era of multi-cancer early detection blood assays

4. Nivolumab plus ipilimumab not effective in localised renal cell carcinoma at high risk of relapse after
    nephrectomy

5. Pembrolizumab plus carboplatin and paclitaxel as first-line therapy for recurrent/metastatic head and
    neck squamous cell carcinoma